These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 8783663)

  • 1. Cytoprotective agents for anthracyclines.
    Dorr RT
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):23-34. PubMed ID: 8783663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
    Lopez M; Vici P
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity.
    Herman EH; Ferrans VJ
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):15-21. PubMed ID: 9768819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
    Jones RL
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals.
    Malisza KL; Hasinoff BB
    Arch Biochem Biophys; 1995 Feb; 316(2):680-8. PubMed ID: 7864623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of amifostine: from cytoprotectant to therapeutic agent.
    Santini V; Giles FJ
    Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dexrazoxane. Current status and prospectives of cardiotoxicity of chemotherapy].
    Lopez M
    Clin Ter; 1999; 150(1):37-49. PubMed ID: 10367544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of selenium, WR-2721, and their combination in the prevention of adriamycin-induced cardiotoxicity in rats.
    Dobrić S; Dragojević-Simić V; Bokonjić D; Milovanović S; Marincić D; Jović P
    J Environ Pathol Toxicol Oncol; 1998; 17(3-4):291-9. PubMed ID: 9726805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin.
    Doroshow JH; Locker GY; Myers CE
    J Clin Invest; 1980 Jan; 65(1):128-35. PubMed ID: 7350193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human heart cytosolic reductases and anthracycline cardiotoxicity.
    Mordente A; Meucci E; Martorana GE; Giardina B; Minotti G
    IUBMB Life; 2001 Jul; 52(1-2):83-8. PubMed ID: 11795600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
    Alderton P; Gross J; Green MD
    Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of anthracycline-induced cardiotoxicity and its prevention.
    Horenstein MS; Vander Heide RS; L'Ecuyer TJ
    Mol Genet Metab; 2000; 71(1-2):436-44. PubMed ID: 11001837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity.
    Minotti G; Mancuso C; Frustaci A; Mordente A; Santini SA; Calafiore AM; Liberi G; Gentiloni N
    J Clin Invest; 1996 Aug; 98(3):650-61. PubMed ID: 8698856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anthracyclines and the heart].
    Mazzarello GP; Morra L
    Recenti Prog Med; 1998 Sep; 89(9):459-64. PubMed ID: 9796378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of anthracycline antibiotics on oxygen radical formation in rat heart.
    Doroshow JH
    Cancer Res; 1983 Feb; 43(2):460-72. PubMed ID: 6293697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo.
    Bjelogrlic SK; Radic J; Radulovic S; Jokanovic M; Jovic V
    Exp Biol Med (Maywood); 2007 Dec; 232(11):1414-24. PubMed ID: 18040065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane.
    Wexler LH
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):86-92. PubMed ID: 9768829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.